Determination of the contribution of cysteinyl leukotrienes and leukotriene B4 in acute inflammatory responses using 5-lipoxygenase- and leukotriene A4 hydrolase-deficient mice.
Arachidonic acid metabolism by 5-lipoxygenase leads to production of the potent inflammatory mediators, leukotriene (LT) B4 and the cysteinyl LT. Relative synthesis of these subclasses of LT, each with different proinflammatory properties, depends on the expression and subsequent activity of LTA4 hydrolase and LTC4 synthase, respectively. LTA4 hydrolase differs from other proteins required for LT synthesis because it is expressed ubiquitously. Also, in vitro studies indicate that it possesses an aminopeptidase activity. Introduction of cysteinyl LT and LTB4 into animals has shown LTB4 is a potent chemoattractant, while the cysteinyl LT alter vascular permeability and smooth muscle tone. It has been impossible to determine the relative contributions of these two classes of LT to inflammatory responses in vivo or to define possible synergy resulting from the synthesis of both classes of mediators. To address this question, we have generated LTA4 hydrolase-deficient mice. These mice develop normally and are healthy. Using these animals, we show that LTA4 hydrolase is required for the production of LTB4 in an in vivo inflammatory response. We show that LTB4 is responsible for the characteristic influx of neutrophils accompanying topical arachidonic acid and that it contributes to the vascular changes seen in this model. In contrast, LTB4 influences only the cellular component of zymosan A-induced peritonitis. Furthermore, LTA4 hydrolase-deficient mice are resistant to platelet-activating factor, identifying LTB4 as one mediator of the physiological changes seen in systemic shock. We do not identify an in vivo role for the aminopeptidase activity of LTA4 hydrolase.
Byrum
R S
RS
Curriculum in Genetics and Molecular Biology, University of North Carolina, Chapel Hill 27599, USA.
Goulet
J L
JL
Snouwaert
J N
JN
Griffiths
R J
RJ
Koller
B H
BH
D000208:Acute Disease; D000707:Anaphylaxis / Q000201:enzymology / Q000235:genetics / Q000276:immunology / Q000503:physiopathology; D000818:Animals; D001094:Arachidonate 5-Lipoxygenase / Q000172:deficiency* / Q000235:genetics*; D016718:Arachidonic Acid / Q000502:physiology; D002465:Cell Movement; D003433:Crosses, Genetic; D003545:Cysteine / Q000502:physiology*; D003877:Dermatitis, Contact / Q000201:enzymology / Q000235:genetics / Q000276:immunology; D004423:Ear / Q000098:blood supply / Q000473:pathology; D004851:Epoxide Hydrolases / Q000172:deficiency* / Q000235:genetics*; D016650:Fluorescein-5-isothiocyanate / Q000008:administration & dosage; D007073:Immunoglobulin E / Q000008:administration & dosage; D018836:Inflammation Mediators / Q000502:physiology*; D007975:Leukotriene B4 / Q000096:biosynthesis / Q000502:physiology*; D015289:Leukotrienes / Q000502:physiology*; D008070:Lipopolysaccharides / Q000008:administration & dosage; D051379:Mice; D018345:Mice, Knockout; D009504:Neutrophils / Q000473:pathology; D010538:Peritonitis / Q000201:enzymology / Q000235:genetics* / Q000276:immunology / Q000503:physiopathology; D010972:Platelet Activating Factor / Q000008:administration & dosage
D018836:Inflammation Mediators; D015289:Leukotrienes; D008070:Lipopolysaccharides; D010972:Platelet Activating Factor; C112381:cysteinyl-leukotriene; D007975:Leukotriene B4; D016718:Arachidonic Acid; D007073:Immunoglobulin E; D001094:Arachidonate 5-Lipoxygenase; D004851:Epoxide Hydrolases; D016650:Fluorescein-5-isothiocyanate; D003545:Cysteine; C043134:leukotriene A4 hydrolase